Early Developability Assessment for Antibody Based Therapeutics

Discover how integrated in silico and in vitro approaches can assess developability, manufacturability, and immunosafety at the earliest stages. Learn how a toolbox strategy enables smarter candidate selection, reduces downstream risk, and supports faster progression of multi-specific antibodies into clinical development.

Key takeaways include:
– Early identification of developability and immunosafety risks in multi-specific antibodies
– How combined in silico and in vitro screening improves lead selection
– Strategies to enhance manufacturability and product quality from the start
– Using a toolbox approach to streamline development and accelerate timelines